Begin main content

Open Calls for Patient Input

This page lists Common Drug Review (CDR) drug applications received by CADTH and the deadlines for filing patient group input for each drug. For more information about how to provide input, please visit the CDR Patient Input page

TBC (fluticasone furoate/umeclidinium/vilanterol)

Indications: Chronic obstructive pulmonary disease (COPD)

Call For Patient Input: January 31, 2018

Patient Input Closed: March 22, 2018

Viberzi (eluxadoline)

Indications: Irritable bowel syndrome with diarrhea

Call For Patient Input: January 25, 2018

Patient Input Closed: March 16, 2018

Fasenra (benralizumab)

Indications: Asthma, severe eosinophilic

Call For Patient Input: January 25, 2018

Patient Input Closed: March 16, 2018

Orkambi (lumacaftor/ivacaftor)

Indications: Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older

Call For Patient Input: January 24, 2018

Patient Input Closed: March 15, 2018

Taltz (ixekizumab)

Indications: Arthritis, psoriatic

Call For Patient Input: January 17, 2018

Patient Input Closed: March 8, 2018

Duodopa (Levodopa / carbidopa (Drug Plan Submission))

Indications: Parkinson's disease

Call For Patient Input: January 11, 2018

Patient Input Closed: March 2, 2018

Dysport Therapeutic (abobotulinumtoxinA)

Indications: lower limb spasticity

Call For Patient Input: January 3, 2018

Patient Input Closed: February 22, 2018